Categories
- ALS Treatment
- Ataxia Treatment
- Autism Treatment
- Batten Disease Treatment
- Brain Injury Treatment
- Cerebral Palsy Treatment
- Epilepsy Treatment
- Femtomedicine
- genetic-medicine
- Hormone Replacement Therapy
- MS Treatment
- Muscular Dystrophy Treatment
- Nanomedicine
- Parkinson's Treatment
- Picomedicine
- Spinal Cord Injury Treatment
- Stem Cell Research
- Stem Cell Therapy
- Stroke Treatment
- Uncategorized
Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
Recommended Sites
- Bed Bug Registry
- Bing Search
- Body Mass Index Calculator
- Broken Link Checker
- Browser Shots
- Cancer Specialist
- Caring Medical
- Cheap Pharmacy Online
- Conscious Evolution
- Cryomedical Blog
- Free Health Insurance Quote
- Free Loan Quote
- Genistein Net
- Google Search
- HGH
- HGH Injections
- HGH Prescription
- HGH Side Effects
- HGH Therapy
- Hormone Decline Graphs / Calculator
- Hormone Therapy
- Human Growth Hormone
- Injectable Testosterone
- International American University
- Medical Dictionary Search
- Medical Drugs Search
- Medical School Review
- Medical Symptoms Search
- New York City Real Estate
- Palm Beach Real Estate
- POLIMEDICAL CENTRO POLISPECIALISTICO
- Quality of Life Assessment
- Ron Paul 2012
- Ron Paul TV
- SEO Web Design
- Start Your Own Internet Services Company
- Stem Cell Therapy for Brain Injury
- Stem Cell Therapy for Cerebral Palsy
- Stem Cell Therapy for Diabetes
- Stem Cell Therapy for Spinal Cord Injury
- Stem Cell Therapy for Stroke
- Stem Cells China
- Testosterone
- Testosterone Therapy
- Topamax Lawsuit
- Website Speed Analysis
- Weight Loss
- WholeSale Domain Names
- Windsor Medical School
- Yahoo Search
-
Category Archives: Nanomedicine
MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapy Start of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical experts Enhanced activities for international partnerships and initiation of discussions with FDA Focus on development partnerships and strategic investors to expand patient access and further reduce development costs Significant decrease in operating expenses expected in 2012 through headcount reduction Berlin, March 26, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the company`s restructuring and revised corporate strategy for 2012. The company reduced its headcount from 52 employees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. Continue reading
Posted in Nanomedicine
Tagged discussion-with, foundation, information, leading-medical, management, medical, therapy, year
Comments Off
Nanostart-Holding MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
FRANKFURT & BERLIN, Germany–(BUSINESS WIRE)– Nanostart(OTCQX:NASRF.PK – News)-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the companys restructuring and revised corporate strategy for 2012. Continue reading
Posted in Nanomedicine
Tagged andreas-jordan, development, european, investment, management, silicon-valley, singaporean, therapy, treatment
Comments Off
Research and Markets: Nanotechnology in Health Care. An In-Depth Investigation of Nanotechnology-Based Therapy
Dublin – Research and Markets (http://www.researchandmarkets.com/research/e0c7cab9/nanotechnology_in) has announced the addition of the “Nanotechnology in Health Care” book to their offering. Nanotechnologies are among the fastest growing areas of scientific research, and this is expected to have a substantial impact on human health care, especially in biomedical applications and nanomedicine now and in the near future. In the present scenario, nanotechnology is spreading its wings to address the key problems in the field of nanomedicine and human health care by improving diagnosis, prevention, treatment, and tissue engineering Continue reading
Posted in Nanomedicine
Tagged address-the-key, and-infectious, applied-aspects, book, dominant, dublin, fatal-diseases, field, human-health, markets-, treatments, various-fields
Comments Off
News Digest: Nanomedicine's potential, business-diversity honor, autism events, school-closure politics, 'green …
Lecture explores nanomedicine’s potential to treat cancer Papyrus writings from 1600 BC describe cancer and attempts at its treatment. Continue reading
Posted in Nanomedicine
Tagged autism-center, business-, community, council, free-, north, physics, rushmer-lecture
Comments Off
Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment
PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR – News), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed by the hepatitis B virus (HBV), the substantial unmet need for chronic HBV infected patients, and how Arrowheads Dynamic Polyconjugate (DPC) enabled RNAi therapeutic in development could potentially address deficiencies of current treatment options. Hepatitis B is a global health problem without effective treatment for a vast number of patients with chronic disease. The World Health Organization estimates that 360 million people, or 5% of the worlds population, suffer from chronic hepatitis B, said Christopher Anzalone, Ph.D., President and CEO of Arrowhead Continue reading
Posted in Nanomedicine
Tagged a-global-health, a-white-paper, ability, biology, hepatitis, highly-specific, markets-, private, research-
Comments Off
Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement
Published on March 5, 2012 at 9:00 AM Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement. With multiple candidates in the clinic addressing a wide range of indications, data demonstrating the power of RNAi as a therapeutic modality are rapidly accumulating Under the terms of the agreement, Axolabs, founded by the principals of former Roche Center of Excellence for RNAi Therapeutics in Kulmbach, Germany, will provide Arrowhead and its partners first-in-class oligonucleotide optimization, synthesis, and analytics Continue reading
Posted in Nanomedicine
Tagged a-leading-role, anzalone, axolabs, clinic, field, oligonucleotide, roland-kreutzer, under-the-terms
Comments Off
ArrowHead Research, Axolabs enter into strategic alliance
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, announced that they have entered into a Strategic Alliance and Master Services Agreement. Under the terms of the agreement, Axolabs will provide Arrowhead and its partners first-in-class oligonucleotide optimization, synthesis, and analytics. These services include bioinformatics for siRNA design; lead identification, optimization and characterization; as well as siRNA synthesis and CMC-related activities Continue reading
Posted in Nanomedicine
Tagged agreement, and-obesity-, arrowhead, axolabs, corporation, entered-into, field, synthesis-and, well-as-sirna
Comments Off
Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi …
PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement. Under the terms of the agreement, Axolabs, founded by the principals of former Roche Center of Excellence for RNAi Therapeutics in Kulmbach, Germany, will provide Arrowhead and its partners first-in-class oligonucleotide optimization, synthesis, and analytics. These services include bioinformatics for siRNA design; lead identification, optimization and characterization; as well as siRNA synthesis and CMC-related activities. Continue reading
Posted in Nanomedicine
Tagged a-leading-role, agreement, anzalone, axolabs, corporation, foundations, oligonucleotide, roland-kreutzer, therapeutics, tool--
Comments Off
A 3-D Brain Tumor Built in a Lab
A team of researchers at Brown University grew a three-dimensional glioma tumor, including the supporting blood vessels, to experiment on it using nanomedicine ways to destroy growths. Not all cancers are created equal Continue reading
Posted in Nanomedicine
Tagged announcement, blood-vessels, journal, petri-dish-type, post, researchers, such-as-glioma, supporting, theranostics-
Comments Off